Mirai Bio Partners with Thermo Fisher Scientific to Accelerate Genetic Medicine Development
核心洞察
Mirai Bio (搜索) and Thermo Fisher Scientific (搜索) have formed a strategic collaboration combining Mirai's machine intelligence platform with Thermo Fisher's manufacturing capabilities to optimize genetic medicine development.
The partnership will leverage Thermo Fisher's cGMP services and commercial manufacturing expertise alongside Mirai's technology for designing tissue-targeted delivery vehicles for nucleic acid therapeutics (搜索).
This collaboration includes a direct investment into Mirai Bio (搜索) as part of Flagship Pioneering (搜索)'s existing partnership with Thermo Fisher, aiming to jointly develop transformative capabilities for the genetic medicine industry.
Mirai Bio (搜索), an innovation partner for genetic medicines founded by Flagship Pioneering (搜索), announced a strategic collaboration with Thermo Fisher Scientific (搜索) to accelerate the development and commercialization of novel nucleic acid therapeutics (搜索). The partnership, announced on May 20, 2025, aims to combine Thermo Fisher's developmental and current Good Manufacturing Practice (cGMP) services with Mirai's machine intelligence-based platform for optimizing genetic medicines.
Under the terms of the agreement, Thermo Fisher will serve as Mirai's preferred pharmaceutical services CDMO (Contract Development and Manufacturing Organization) for cGMP services and commercial manufacturing. This collaboration is designed to enhance Mirai's end-to-end platform capabilities available to its partners in the life sciences and genetic medicines marketplace.
Combining Advanced Technologies for Genetic Medicine Innovation
Mirai Bio (搜索)'s proprietary platform enables high-throughput design and in vivo testing of tissue-targeted delivery vehicles for genetic medicines. The company's technology facilitates seamless, rapid industrialization of development candidates by addressing key limitations in delivery, design, and manufacturing of genetic medicines.
"Thermo Fisher is a trusted industry leader with deep technical expertise and proven developmental and GMP services and commercial manufacturing capabilities," said Travis Wilson, Executive Chairman of Mirai and Growth Partner at Flagship Pioneering (搜索). "Coupling these with Mirai's unique delivery and genetic medicine optimization technologies will support accelerated program development and commercialization for our life science partners worldwide."
The collaboration will initially leverage the capabilities of Thermo Fisher's state-of-the-art facility for RNA and Advanced Formulations. This strategic engagement includes a direct investment into Mirai as part of Flagship's existing partnership with Thermo Fisher, which seeks to jointly develop transformative capabilities for the industry.
Addressing Current Limitations in Genetic Medicine
Vincent Hingot, president of Drug Substance, Pharma Services at Thermo Fisher, emphasized the significance of the partnership: "Mirai is on a journey to break down the barriers currently limiting the full potential of genetic medicines and offer fully integrated design, delivery and manufacturing capabilities to innovative partners. We're excited to combine our life sciences expertise and manufacturing capabilities with Mirai's machine intelligence-powered platform to help bring the next generation of medicines to patients in need."
Founded in 2021, Mirai Bio (搜索) has built an open platform driven by machine intelligence that aims to solve key limitations hindering today's genetic medicines. The company's approach combines generative design of precise delivery solutions co-optimized with manufacturing processes to develop the future of genetic medicine.
Expanding Industry Partnerships
This collaboration represents an expansion of Flagship Pioneering (搜索)'s long-standing relationship with Thermo Fisher Scientific (搜索).
"This collaboration is an expansion of our long-standing relationship with Thermo Fisher and a reflection of our shared vision for accelerating the development of enabling technologies to develop first-in-class therapies," said Justine Levin-Allerhand, Ph.D., Executive Partner, Origination and Corporate Development at Flagship. "In this case, the combination of Mirai's innovation in targeted delivery and cargo design and Thermo Fisher's deep technical and commercial manufacturing expertise will maximize opportunities for the co-creation of novel medicines and help realize the full potential of both enterprises."
The partnership highlights a growing trend in the genetic medicine sector toward collaborative models that integrate specialized expertise across the development and manufacturing continuum. By combining Mirai's innovative platform with Thermo Fisher's established manufacturing capabilities, the collaboration aims to address critical challenges in bringing genetic medicines from concept to commercialization.